| 货号 | HC359106 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 宿主 | Human |
|---|
| 同种型 | IgG |
|---|
| 克隆号 | AO-176 |
|---|
| 生物活性 | AO-176 shows EC 50 values of 130 ng/mL (OV90), 390 ng/mL (HCC827), 649 ng/mL (SNU-1), 250 ng/mL (OV10-315), 2700 ng/mL (MDA-MB-231), 390 ng/mL (Jurkat) and 1910 ng/mL (Raji) [1]. AO-176 (10 ug/mL, 24 h) induces death of Jurkat and OV90 cells [1]. AO-176 (0.017-1000 ug/mL) binds negligibly to RBCs and does not cause agglutination of washed human RBCs [1][3]. AO-176 (10-30 ug/mL, 24 h) has no killing effect on normal cell and the activated T cells [1]. AO-176 (0.001-100 ug/mL, 90 min) directly inhibits the binding of SIRPα to CD47 on Jurkat cells with an IC 50 of 0.78 to 0.87 ug/mL [1]. AO-176 (0.01-10 ug/mL, 2 h) promotes the phagocytosis of both Jurkat, Raji, OV90, Detroit 562, and FaDu cells in a concentration-dependent manner [1][2][4]. AO-176 (1-25 mg/kg, i.v., weekly for 4 weeks) significantly suppresses the tumor growth in Raji lymphoma xenograft mice models [1]. AO-176 (10-25 mg/kg, i.p., weekly or 5 times/weeks for 5-6 weeks) significantly suppresses the tumor growth in MDA-MB-23, SNU-1 and OV90 xenograft mice models [1]. AO-176 (3-25 mg/kg) exerts anti-tumor activity in RPMI-8226 and NCI-H929 xenografted mice models [3][4]. . |
|---|
| 表达系统 | Mammalian cells |
|---|
| 克隆类型 | Monoclonal |
|---|
| 靶标 | Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6 |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | Q08722 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | AO-176, AO176, AO176 |
|---|
| 背景 | Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical). 1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 115095943. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 190048354. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 76918315. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 85505626. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621 |
|---|
| 文献 | 1. Puro RJ, et al. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846. [HC359106]
2. Andrejeva G, et al. Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. J Immunol. 2021 Feb 15;206(4):712-721. [HC359106]
3. William Casey Wilson, et al. AO-176, a Highly Differentiated Clinical Stage AntiCD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics. Blood (2020) 136 (Supplement 1): 3–4 [HC359106]
4. John Richards, et al.. Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination. Blood (2019) 134 (Supplement_1): 1844. View More [HC359106] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
